Last reviewed · How we verify
PEG-IFNalfa2a
At a glance
| Generic name | PEG-IFNalfa2a |
|---|---|
| Sponsor | Human Genome Sciences Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-IFNalfa2a CI brief — competitive landscape report
- PEG-IFNalfa2a updates RSS · CI watch RSS
- Human Genome Sciences Inc. portfolio CI